



European Monitoring Centre  
for Drugs and Drug Addiction

PROGRAMME

# Continuity and change: high-risk drug use and drug treatment in Europe 2014

EMCDDA event incorporating the annual expert meeting of the treatment demand indicator and the annual meeting of the high-risk drug use indicator (formerly known as problem drug use (PDU))

23–26 September 2014  
**EMCDDA, Lisbon**

## | Continuity and change: high-risk drug use and drug treatment in Europe 2014

Tuesday 23 September 2014

**TDI and HRDU annual expert meetings: methodological part**  
(only for national experts)

09.00–17.00	These two meetings on the methodological parts of the key indicators will run in parallel. The detailed agendas for these parts will be available as separate documents to the respective national experts.
-------------	--

Wednesday 24 September 2014			
Opioids, benzodiazepines, stimulants			
08:40	Registration open		
09.00	Background, objectives and expected outcomes of the event — Paul Griffiths		
	<b>Trends and developments in high-risk opioid use: a multi-indicator perspective</b> — Chairs: Julian Vicente and Linda Montanari, Discussant: Julian Vicente		
	Prevalence of and trends in opioid use in Europe: a multi-indicator perspective — Danica Thanki and Linda Montanari		
	Long-term trends in opioid use in the USA: possible resurgence of heroin — Michael A. Cala		
	Recent strong decrease of opioid use in Austria: a cross-indicator analysis — Alexander Grabenhofer-Eggerth		
	Estimating the number of and trends in opiate, cocaine, and amphetamine users in Berlin — Ludwig Kraus		
11.00	Coffee break		
11.30	<b>Opioid treatment coverage and treatment need</b> — Chairs: Dagmar Hedrich and Danica Thanki		
	Current trends in opioid substitution treatment: saturation or unmet need? — Alessandro Pirona		
	Participation in OST treatment and HRDU estimates: a data analysis — Danica Thanki and Eleni Kalamara		
	Substitution treatment coverage calculation in Norway — Ellen Amundsen		
	In-depth analysis of substitution treatment data in combination with other data (e.g. police) and theoretical considerations to identify stable clients — Martin Busch		
13.00	Lunch break		
	<b>Parallel sessions</b>		
14.00	Conference Centre	Room 107	Room 012
	<p><b>Parallel session 1: Ageing drug users: situation, co-morbidities and responses</b></p> <p>Chair: Jane Mounteney</p> <p>Discussant: Alessandro Pirona</p> <ul style="list-style-type: none"> <li>• Tim Millar: Mortality and treatment interventions among 200 000 opioid users in England, 2005–09</li> <li>• Andrej Kastelic: Do we need special programs for ageing drug users?</li> <li>• Lubomir Okruhlica: Main medical problems of ageing PDUs in OST</li> <li>• Saket Priyadarshi: Multimorbidity in ageing drug users – a Scottish perspective</li> </ul>	<p><b>Parallel session 2: Vulnerable populations and drug problems</b></p> <p>Chair: Linda Montanari</p> <p>Discussant: Stefann Enggist</p> <ul style="list-style-type: none"> <li>• Kieran Lynch: Public health needs of prisoners in English prisons</li> <li>• Nicoletta Capra: An innovative model of assessment and intervention for drug-addicted mothers and their children: clinical and research issues</li> <li>• Dike van de Mheen: The prevalence and course of substance use among Dutch homeless people and the relationship with housing situation after 1.5 years</li> </ul>	<p><b>Parallel session 3: Monitoring systems and information technologies in drug use and drug treatment data collection</b></p> <p>Chair: André Noor</p> <p>Discussant: Luis Royuela</p> <ul style="list-style-type: none"> <li>• Naseeba Alozaibi: Developing a surveillance system in United Arab Emirates: challenges and opportunities</li> <li>• Bruno Genetti: The Italian interactive system for addiction data management</li> <li>• Bruno Guarita: Data management of the largest EMCDDA data set – TDI</li> </ul>

		<ul style="list-style-type: none"> <li>• Suzi Lyons: Travellers and problem drug use in Ireland</li> <li>• Bogdan Gheorghe: Drug consumption among Roma population</li> </ul>	<ul style="list-style-type: none"> <li>• Wil Kuijpers: LADIS, the Dutch Information System on Alcohol and Drugs</li> <li>• Andrew Jones: NDTMS – a perspective on the English system</li> </ul>
15.45	Coffee break		
16.15	<p><b>The added value of treatment systems approach in services planning</b></p> <p>Chair: Alessandro Pirona</p> <p>Discussant: Roland Simon</p> <p>How system-based treatment monitoring can inform policy-making — Kerstin Stenius</p> <p>A systems approach to substance use in Canada — Rebecca Jesseman</p> <p>Panel discussion</p>		
18.00	Cocktail at the EMCDDA premises		

Thursday 25 September 2014			
	<b>Parallel sessions</b>		
09.30	Conference Centre <b>Parallel session 4: Stimulant drugs</b> Chair: Danica Thanki Discussant: Martta Forsell <ul style="list-style-type: none"> <li>• Tomasz Bialas: The effects of the State Sanitary Inspectorate activity in the field of new psychoactive substances (NPS)</li> <li>• Róbert Csák: Update on synthetic cathinones injection in Hungary</li> <li>• Bogdan Gheorghe: Update on synthetic cathinones injection in Romania</li> <li>• Zuzana Alexandercikova: Risk of HCV infection among heroin and methamphetamine users</li> </ul>	Room 107 <b>Parallel session 5: High-risk benzodiazepine use</b> Chairs: Klaudia Palczak and Michael-Evans Brown Discussant: Saket Priyadarshi <ul style="list-style-type: none"> <li>• Felice Nava: (Mis)use of benzodiazepines among high-risk drug users</li> <li>• Linda Montanari: Clients demanding treatment for use of benzodiazepines in Europe</li> <li>• Lubomir Okruhlica: Clinical perspective on implications of use of benzodiazepines among clients of drug treatment services — challenges and best practice</li> </ul>	Room 012 <b>Parallel session 6: Adaptation of drug treatment in the situation of changing needs</b> Chair: Roland Simon Discussant: Rebecca Jesseman <ul style="list-style-type: none"> <li>• Domingos Duran: Therapeutic communities: adaptations and the role of monitoring</li> <li>• Wibke Voigt: A clinical view from inpatient treatment: adaptations and the role of monitoring</li> <li>• Rosario Sendino: A quasi-federal view: adaptations and the role of monitoring</li> <li>• Barbara Braun: Monitoring facilities vs. monitoring service provision: a national discussion</li> </ul>
11.00	Coffee break		
<b>High-risk cannabis use</b>			
11.30	Chairs: Linda Montanari and Julian Vicente Discussant: Jacek Moskalewicz Trends in high-risk cannabis use in treatment demand and multi-indicator analysis — Linda Montanari and Danica Thanki Cannabis treatment: the EMCDDA Insights — Marica Ferri Trends in cannabis use and cannabis-related treatment demand in Switzerland — Etienne Maffli Cannabis use in France — Tanja Bastianic Psychiatric comorbidity and cannabis use — Maria Francina Fonseca Casals		
13.00	Lunch break		
<b>Economic recession, treatment outcomes and costs</b>			
14.00	<b>Cost of treatment and the impact of economic recession on drug users and drug treatment</b> Chair: Cláudia Costa Storti Discussants: Pedro Pita Barros, Ricardo Gonçalves The impact of economic recession on funding of drug services across EU and Norway — Cláudia Costa Storti National income inequality and declining GDP growth rates are associated with increases in HIV diagnoses among people who inject drugs in Europe — Clive Richardson Designing and implementing responsive drug policies under fiscal constraints: the case of Greece — Meni Malliori Estimating OST costs in Italy — Bruno Genetti		
15.30	Coffee break		

16.00	<b>Treatment outcomes</b> Chair: Marica Ferri Discussant: Andrew Jones What are the outcomes for assessing drug treatment? A review of long-term observational studies on the treatment of opioid dependence — Lucas Wiessing Risk taking and outcomes in the English treatment system — Andrew Jones What can nine years of treatment data demonstrate about long term outcomes, cost effectiveness and the changing profile of drug use in England — Jonathan Knight
17.30	End of the day

Friday 26 September 2014	
09.00	<p><b>Evaluating best practice: can we monitor treatment effectiveness across Europe?</b></p> <p>Chairs: Marica Ferri and Lucas Wiessing</p> <p>Making sense of available data: developing a framework to support knowledge exchange — Marica Ferri, Alessandra Bo</p> <p>Drug treatment monitoring and evidence based practice. A mechanism for improving quality and outcomes? — Jonathan Knight and Luke Mitcheson</p> <p>Combination interventions to prevent health related problems in people who inject drugs — can they be monitored using routine data? — Peter Vickerman</p> <p>How can modelling contribute to the evaluation of drug treatment in Europe? — Catherine Comiskey</p> <p>New indicators for monitoring drug users health: a comparison across countries — Carla Rossi</p>
11.00	Coffee break
11.30	Wrap-up and conclusions of the session
12.00	<b>Closing remarks on the overall EMCDDA event</b> — Roland Simon and Julian Vicente